Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Newly released survey data revealed the following key trends for GLP-1 drug coverage: 60% of employers provide coverage for diabetes only (on the rise from 55% in 2025, 57% in 2024 and 49% in 2023) 36% provide coverage for both diabetes and weight loss (same as 2025, up from 34% in 2024 and 26% in 2023) 45% cover GLP-1 drugs for other FDA-approved conditions (sleep apnea, cardiovascular disease, etc.) Among employers not covering GLP-1 drugs for weight loss, 9% are considering adding coverage for weight loss
Ishino, Y
W.RosenstockJ.CananiL
GLP-1 receptor agonists approved for use in the UK include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia)
US$ 24.74
.jpeg)
US$ 23.96
US$ 27.80
US$ 25.84
US$ 24.00
US$ 24.65
US$ 20.56
